Representative nanoengineering strategies include pH-responsive alginate coatings that co-encapsulate Escherichia coli Nissle 1917 (EcN) with 5-aminosalicylic acid, enabling simultaneous intestinal release of live bacteria and drug to modulate the microbiota, suppress pro-inflammatory cytokines, and repair the intestinal barrier (Peng et al., 2023)
Nausea, diarrhea, vomiting, constipation, reflux, and reduced appetite are most common
Medical guidance and dosage monitoring can reduce potential risks
Fatigue Some people experience fatigue, particularly in the first few weeks at new doses
The medication should generally be kept refrigerated, but it can withstand short periods of travel
And here is what most people discover the hard way: conventional treatments often manage symptoms without addressing the underlying tissue damage that keeps the pain cycle spinning